Business
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome Trial San...
About this update from Thiogenesis Therapeutics Corp
[{"type":"text","content":"Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside WebinarDr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome TrialSan Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (\"Thiogenesis\" or the \"Company\"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate as a panelist in the United Mitochondrial Disease Foundation's (\"UMDF\") 2026 Bench-to-Bedside webinar on January 5, 2026.During the session, Dr. Rioux will provide clinical updates on Thiogenesis' lead product candidate, TTI-0102, including an update on the Company's Phase 2 clinical program in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (\"MELAS\"), as well as plans for its upcoming Phase 2a clinical trial in Leigh syndrome spectrum (\"LSS\") in the United States.Thiogenesis' two lead clinical programs include:An EU Phase 2 clinical trial in MELAS that was conducted at leading academic medical centers in Europe and recently completedA planned Phase 2a U.S. clinical trial in Leigh syndrome spectrum, expected to initiate in the first quarter of 2026 in collaboration with a leading pediatric hospital\"I am pleased to participate in UMDF's Bench-to-Bedside webinar and to provide an update on Thiogenesis' clinical programs in MELAS and Leigh syndrome spectrum,\" said Patrice Rioux, MD, Ph.D., Chief Executive Officer and Co-Founder of Thiogenesis. \"TTI-0102 is being developed to address mitochondrial oxidative stress, a central pathological feature of multiple inherited mitochondrial disorders for which there are currently no approved therapies.\"About UMDFThe United Mitochondrial Disease Foundation's mission is to promote research and education for the diagnosis, treatment, and cure of mitochondrial disorders and to provide support to affected individuals and families. For more than 25 years, UMDF has supported a global network of clinicians, researchers, and patient advocates dedicated to advancing mitochondrial disease research and improving patient outcomes.About MELAS Mitochondrial encephalopathy with lactic acidosis and...